TELA’s management is scheduled to present at the Canaccord MedTech, Diagnostics and
About
Investor Contact
332-895-3230
ir@telabio.com
Source:
2022 GlobeNewswire, Inc., source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.15 USD | -0.39% | +4.15% | -22.21% |
Apr. 15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
Mar. 22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
TELA’s management is scheduled to present at the Canaccord MedTech, Diagnostics and
About
Investor Contact
332-895-3230
ir@telabio.com
Source:
2022 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-22.21% | 127M | |
-4.36% | 184B | |
-3.87% | 105B | |
-4.38% | 67.09B | |
+8.23% | 51.61B | |
+15.54% | 47.55B | |
-2.75% | 39.95B | |
+7.16% | 27.62B | |
-12.48% | 25.74B | |
-1.68% | 25.62B |